Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of nerandomilast in systemic sclerosis
MOH_2026-10-06_017064Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Fexinidazole in systemic sclerosis (SSc) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Time to first occurrence of disease progression or death from any cause. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
Fexinidazole
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on MOH_2026-10-06_017064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-10-06_017064.